Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apexigen, Inc. stock logo
APGN
Apexigen
$0.39
$0.39
$0.33
$8.28
$9.57M3.6967,731 shsN/A
Discover Financial Services stock logo
DFS
Discover Financial Services
$197.76
-1.4%
$196.61
$122.37
$207.42
$49.77B1.161.85 million shs31.29 million shs
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
$104.62
+2.0%
$92.24
$57.45
$127.50
$9.27B1.81.69 million shs2.23 million shs
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$68.49
$68.47
$21.65
$73.02
$4.62B0.452.07 million shs74 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apexigen, Inc. stock logo
APGN
Apexigen
0.00%0.00%0.00%0.00%0.00%
Discover Financial Services stock logo
DFS
Discover Financial Services
0.00%0.00%0.00%+15.50%+53.47%
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
-0.25%+4.99%+8.77%+23.47%+39.96%
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apexigen, Inc. stock logo
APGN
Apexigen
N/AN/AN/AN/AN/AN/AN/AN/A
Discover Financial Services stock logo
DFS
Discover Financial Services
2.9133 of 5 stars
1.30.04.23.90.61.72.5
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
4.4869 of 5 stars
3.43.00.00.03.34.23.1
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apexigen, Inc. stock logo
APGN
Apexigen
0.00
N/AN/AN/A
Discover Financial Services stock logo
DFS
Discover Financial Services
2.58
Moderate Buy$191.64-3.09% Downside
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
2.81
Moderate Buy$116.1010.97% Upside
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest H24, FOUR, APGN, DFS, and GBT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$95.00 ➝ $110.00
6/5/2025
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$124.00
6/2/2025
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/2/2025
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$97.00
5/7/2025
Discover Financial Services stock logo
DFS
Discover Financial Services
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$180.00
4/30/2025
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
4/30/2025
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$154.00 ➝ $127.00
4/30/2025
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$100.00 ➝ $111.00
4/30/2025
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
Susquehanna
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetPositive ➝ Positive$100.00 ➝ $125.00
4/30/2025
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/30/2025
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$138.00 ➝ $125.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apexigen, Inc. stock logo
APGN
Apexigen
N/AN/AN/AN/A($0.09) per shareN/A
Discover Financial Services stock logo
DFS
Discover Financial Services
$18.00B2.76$11.59 per share17.06$71.33 per share2.77
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
$3.33B2.78$6.96 per share15.04$11.43 per share9.15
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$194.75M23.73N/AN/A$3.05 per share22.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apexigen, Inc. stock logo
APGN
Apexigen
-$32.07MN/A0.00N/AN/A-614.82%-133.30%N/A
Discover Financial Services stock logo
DFS
Discover Financial Services
$4.54B$19.1112.3912.521.5117.29%26.18%2.72%7/16/2025 (Estimated)
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
$229.60M$2.9635.3422.210.756.50%32.97%7.17%7/29/2025 (Estimated)
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/A

Latest H24, FOUR, APGN, DFS, and GBT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/16/2025Q2 2025
Discover Financial Services stock logo
DFS
Discover Financial Services
$3.46N/AN/AN/A$4.34 billionN/A
4/29/2025Q1 2025
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
$0.76$1.07+$0.31$0.20$886.09 million$368.50 million
4/23/2025Q1 2025
Discover Financial Services stock logo
DFS
Discover Financial Services
$3.33$4.25+$0.92$4.25$4.25 billion$4.25 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apexigen, Inc. stock logo
APGN
Apexigen
N/AN/AN/AN/AN/A
Discover Financial Services stock logo
DFS
Discover Financial Services
$2.801.42%N/A14.65%14 Years
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
N/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apexigen, Inc. stock logo
APGN
Apexigen
N/A
0.82
0.82
Discover Financial Services stock logo
DFS
Discover Financial Services
1.09
1.09
1.03
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
2.12
1.36
1.36
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
4.92
6.88
6.17

Institutional Ownership

CompanyInstitutional Ownership
Apexigen, Inc. stock logo
APGN
Apexigen
13.65%
Discover Financial Services stock logo
DFS
Discover Financial Services
86.94%
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
98.87%
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Apexigen, Inc. stock logo
APGN
Apexigen
19.20%
Discover Financial Services stock logo
DFS
Discover Financial Services
0.69%
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
25.15%
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
4.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apexigen, Inc. stock logo
APGN
Apexigen
1124.86 million20.09 millionNot Optionable
Discover Financial Services stock logo
DFS
Discover Financial Services
20,200251.65 million249.58 millionOptionable
Shift4 Payments, Inc. stock logo
FOUR
Shift4 Payments
4,00088.62 million66.33 millionOptionable
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
45767.48 million64.17 millionOptionable

Recent News About These Companies

GBT LIVE! with Faye Donald
Global Blood Therapeutics Inc (GBT)
US judge schedules Amex GBT-CWT merger trial for September
US DOJ files lawsuit to block Amex GBT acquisition of CWT
U.S. Justice Department sues to block Amex GBT-CWT deal
US Files Antitrust Suit to Block Amex GBT-CWT Travel Merger (2)
GBT Technologies to acquire Nexus Workspaces from CGI
CT Partners appoint CEO to Advantage GBT Advisory Board
GBT, Robinson Properties to Develop Mixed-Use Project in Metro Nashville
GBT Realty Breaks Ground on 42,000 SF Retail Project in Kyle, Texas
GBT heads to FDA with sickle cell drug voxelotor

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Apexigen stock logo

Apexigen NASDAQ:APGN

Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.

Discover Financial Services stock logo

Discover Financial Services NYSE:DFS

$197.76 -2.73 (-1.36%)
Closing price 05/16/2025
Extended Trading
$197.76 0.00 (0.00%)
As of 05/16/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Discover Financial Services, through its subsidiaries, provides digital banking products and services, and payment services in the United States. It operates in two segments, Digital Banking and Payment Services. The Digital Banking segment offers Discover-branded credit cards to individuals; personal loans, home loans, and other consumer lending; and direct-to-consumer deposit products comprising savings accounts, certificates of deposit, money market accounts, IRA certificates of deposit, IRA savings accounts and checking accounts, and sweep accounts. The Payment Services segment operates the PULSE to access automated teller machines, debit, and electronic funds transfer network; and Diners Club International, a payments network that issues Diners Club branded charge cards and/or provides card acceptance services, as well as offers payment transaction processing and settlement services. The company was incorporated in 1960 and is based in Riverwoods, Illinois.

Shift4 Payments stock logo

Shift4 Payments NYSE:FOUR

$104.62 +2.06 (+2.01%)
Closing price 03:57 PM Eastern
Extended Trading
$104.75 +0.13 (+0.12%)
As of 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Shift4 Payments, Inc. (NYSE FOUR) provides integrated payment processing and technology solutions in the United States. Its payments platform provides omni-channel card acceptance and processing solutions, including end-to-end payment processing for various payment types; merchant acquiring; proprietary omni-channel gateway; complementary software integrations; integrated and mobile point-of-sale (POS) solutions; security and risk management solutions; and reporting and analytical tools, as well as tokenization, risk management/underwriting, payment device and chargeback management, fraud prevention, and gift card solutions. The company also offers suite of technology solutions, such as Lighthouse, a cloud-based business intelligence tool that includes customer engagement, social media management, online reputation management, scheduling, and product pricing, as well as reporting and analytics; integrated POS for merchants business; and Skytab, a mobile payment solution. In addition, it provides marketplace technology that enable seamless integrations into third-party applications, which includes online delivery services, payroll, timekeeping, and other human resource services. Further, the company offers merchant management, training and education, marketing management, and incentives tracking solutions. Additionally, it provides merchant underwriting, onboarding and activation, training, risk management, and support services; and software integrations and compliance management, and partner support and services. The company was founded in 1998 and is headquartered in Allentown, Pennsylvania.

Global Blood Therapeutics stock logo

Global Blood Therapeutics NASDAQ:GBT

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.